« Back to Farmacia Journal 5/2017

EFFECT OF ULINASTATIN COMBINED WITH HAEMODIALYSIS ON SEVERE ACUTE PANCREATITIS

HANFEI XING ¹, HUI WEN ^2*, DUJIE WANG ¹, HONGHUI WANG ¹, MENG ZHAO ²

Download Full Article PDF

This study aimed to explore the clinical efficacy of ulinastatin and haemodialysis in the treatment of severe acute pancreatitis (SAP). 60 SAP patients treated in the Binzhou Central Hospital in Shandong Province, China, during June 2015 and December 2016 were randomly selected as the research subjects in this study and divided into a conventional treatment group A and an ulinastatin combined with haemodialysis treatment group B. The clinical data of the patients were compared and the blood amylase, urine amylase, serum urea nitrogen, serum lactose, serum creatinine levels, CD4+, CD8+, interleukin-1 (IL-1) and tumour necrosis factor-alpha (TNF-α) ratio were compared after treatment. The levels of serum amylase, urinary amylase, serum creatinine, serum urea nitrogen and serum lactose of group B decreased with the increase of treatment time and showed a significant difference when compared with the conventional treatment group (p < 0.05); IL-1 and TNF-α levels decreased, CD4+, CD8+ and the ratio of both increased gradually. The improvement of the clinical symptoms such as fever, abdominal pain and swelling in group B was shorter than in group A (p < 0.05). The cure rate of group B was about 50% and its total effective rate was about 93.3% while those of group A was about 26.7% and 53.3% (p < 0.05). Ulinastatin combined with haemodialysis has a good clinical effect on severe acute pancreatitis.